USSF collaboration (VaxForm) amongst the select few on list of nextgen SARS-CoV-2 mucosal vaccine candidates in use or in clinical development.

April 12, 2023

A priority goal for next-generation COVID-19 vaccines is to reduce infection with and transmission of SARS-CoV-2 via the respiratory route, while maintaining or enhancing protection against symptomatic and severe disease. Utilization of mucosal vaccination to elicit robust mucosal immunity in the respiratory tract is a logical approach to achieving these goals.

Read More

Comments are closed.